Novartis has shared positive top-line results from a late-stage study of its investigational gene therapy in patients aged two to less than 18 years with the rare neuromuscular disease spinal muscular ...

Bray has spinal muscular atrophy, a rare degenerative disease that's gradually robbed him of the ability to move his muscles ... with Jeremy," but didn't show a willingness to change the ...

Spinal muscular atrophy, or SMA, is a genetic disorder that is divided ... Additional testing, such as electromyography (which measures electric activity in muscles) or muscle biopsy (taking a sample ...

Due to the progressive nature of spinal muscular atrophy (SMA) — a rare genetic disease ... Historically, electromyography, nerve conduction tests, and muscle biopsy were the main methods used to ...

Investing.com -- Novartis AG (SIX:NOVN) has reported that an advanced study showed their new experimental drug improved motor function in children suffering from a form of spinal muscular atrophy.

Back to Healio Topline results from a phase 3 clinical trial showed an investigational gene therapy for young people with spinal muscular atrophy type 2 increased mobility and slowed disease ...

Investing.com -- Novartis (LON:0QLR) AG (SIX:NOVN) has reported that an advanced study showed their new experimental drug improved motor function in children suffering from a form of spinal muscular ...

Positive results from its Phase III STEER study mean Novartis could boost sales of its OAV101 IT drug for spinal muscular ...

—A new study analyzed health-related quality of life (HRQoL) using 5 generic and neuromuscular disease-specific rating scales in German children with spinal muscular atrophy (SMA), most of whom ...